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Abstract
Clinical and preclinical data demonstrate that altered pulmonary physiology (including increased
inflammation, increased blood flow, airway resistance, and hyper-reactivity) is an intrinsic compo-
nent of Sickle Cell Disease (SCD) and may contribute to excess SCD morbidity and mortality.
Inhaled corticosteroids (ICS), a safe and effective therapy for pulmonary inflammation in asthma,
may ameliorate the altered pulmonary physiologic milieu in SCD. With this single-center, longitudi-
nal, randomized, triple-blind, placebo controlled trial we studied the efficacy and feasibility of ICS
in 54 nonasthmatic individuals with SCD. Participants received once daily mometasone furoate
220 mcg dry powder inhalation or placebo for 16 weeks. The primary outcome was feasibility (the
number who complete the trial divided by the total number enrolled) with prespecified efficacy out-
comes including daily pain score over time (patient reported) and change in soluble vascular cell
adhesion molecule (sVCAM) levels between entry and 8-weeks. For the primary outcome of feasibil-
ity, the result was 96% (52 of 54, 95% CI 87%-99%) for the intent-to-treat analysis and 83% (45 of
54, 95% CI 71%-91%) for the per-protocol analysis. The adjusted treatment effect of mometasone
was a reduction in daily pain score of 1.42 points (95%CI 0.61-2.21, P50.001). Mometasone was
associated with a reduction in sVCAM levels of 526.94 ng/mL more than placebo (95% CI 50.66-
1003.23, P50.03). These results support further study of ICS in SCD including multicenter trials
and longer durations of treatment. www.clinicaltrials.gov (NCT02061202)
1 | INTRODUCTION
Sickle Cell Disease (SCD) is an autosomal recessive disorder of hemo-
globin characterized by chronic hemolysis and altered blood rheology
with clinical manifestations that include pain, progressive organ dam-
age, and shortened lifespan.1 The lung plays an essential role in SCD
pathophysiology as it is the only organ that reverses red cell sickling,
which occurs during hemoglobin deoxygenation. A growing body of
clinical and preclinical data demonstrates that altered pulmonary physi-
ology (including increased inflammation, increased blood flow, airway
resistance, and hyperreactivity) is an intrinsic component of SCD and
may contribute to excess SCD morbidity and mortality.2–6 Therapies to
ameliorate the altered pulmonary physiologic milieu in SCD are a prom-
ising avenue for disease modification.
Comorbid asthma is a well-established risk factor for increased
SCD morbidity and mortality, and more recent observational research
identified high rates of airway hyperreactivity, obstruction, and wheez-
ing in individuals with SCD who do not have asthma.7–16 Several stud-
ies demonstrated a link between the presence of respiratory symptoms
and SCD complications including pain, acute chest syndrome, and
death.9,17–19 In one prospective cohort of nonasthmatic individuals
with SCD, the rate of pain episodes doubled during 8-week periods
after self-reported cough or wheeze (mostly in the setting of upper
respiratory infection as patients with asthma were excluded) and there
was a trend towards increased rates of acute chest syndrome.13 These
data and other observational studies suggested a temporal link
between respiratory symptoms and SCD pain, raising the question of
whether therapies aimed at reversing airway obstruction and inflamma-
tion could benefit nonasthmatic individuals with SCD, particularly after
periods of self-reported wheeze or cough.
The etiology of nonasthmatic lung function abnormalities in SCD is
an area of ongoing investigation. Sickle mice demonstrate elevated
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airway inflammation, higher levels of pulmonary CD41 and CD81 T
cells and myeloid activation chemokines.6,20,21 This inflammation does
not appear to be driven exclusively by eosinophilic processes in
humans as levels of exhaled nitric oxide (eNO) are only slightly higher
in SCD compared with healthy controls but not as high as individuals
with poorly controlled asthma.22,23 Given these data, anti-inflammatory
asthma therapies (oral leukotriene inhibitors24 and inhaled corticoste-
roids) are promising as adjuvant SCD therapy. Emerging data suggest
that elevated pulmonary capillary blood volume and flow (resulting
from chronic anemia) are important contributors to the observed
increase in airway resistance in SCD25 and therefore therapies (such as
hydroxyurea and transfusion) aimed at ameliorating the high flow state
may have greater benefit than bronchodilators. While hydroxyurea is
associated with improvements in lung function, transfusion resulted in
further increases in pulmonary capillary blood volume and airway
resistance.26 With this study, we aimed to evaluate the efficacy and
feasibility of inhaled corticosteroids (ICS) for individuals with SCD who
do not have asthma.
2 | METHODS
2.1 | Study design and conduct
With this single-site, randomized, placebo-controlled, triple-blind phase
II trial, we tested the hypothesis that in nonasthmatic individuals with
SCD who report recent cough or wheeze, ICS administered for a 16-
week period will reduce SCD-related complications, improve patient-
reported outcomes and reduce biological markers of pulmonary inflam-
mation and vascular injury in comparison to placebo. We also tested
protocol fidelity and feasibility in preparation for a future multisite trial.
The single primary endpoint for the trial was feasibility (defined as the
number of participants who meet criteria for per-protocol analysis of
all clinical and biologic outcomes divided by the total number enrolled)
however we did specify a priori patient-reported (daily pain diary
scores over time) and biologic outcomes (change in sVCAM and change
in eNO between zero and eight weeks). To meet criteria for per-
protocol analyses, participants were required to maintain at least 70%
adherence to study medication, complete the 8-week (1/- 2 weeks)
assessment of biological outcomes (spirometry, blood draw, and ques-
tionnaires), and fill out at least 30 pain diaries. The intent-to-treat anal-
ysis included all participants except those who were lost to follow-up
prior to the first data collection point (two individuals were lost, and
had no data for analysis). The target sample size was 45 participants
with a 2:1 allocation to drug vs. placebo. A sample size calculation was
performed for the a priori patient-reported outcome of daily pain diary
scores. To detect a difference in mean pain score of 1 point for ICS vs.
placebo we estimated a power of 0.80 with a sample size of 45 (30
drug, 15 placebo) at a two-sided alpha level of 0.05 and autoregressive
correlation of intra-individual scores of 0.20. This study was approved
by the Mount Sinai Program for Protection of Human Subjects. The
trial was conducted under an FDA investigational new drug application
(IND 117997) and registered with clinicaltrials.gov (NCT02061202).
Each participant provided written informed consent. A complete sched-
ule of protocol changes is included in the supplement. Protocol
changes were minor and had no effect on the intervention, study out-
comes or the intent to treat analyses.
2.2 | Patients
Eligibility criteria for the study were HbSS or HbSb0 thalassemia (con-
firmed by electrophoresis), age 15 or older and a patient self-report of
cough or wheeze over the preceding two months. Exclusion criteria
included a diagnosis of asthma, incarceration, pregnancy, more than 15
ED visits for SCD pain over the prior 12 months and discharge from
the hospital within the previous 7 days. Specifically, patients with
asthma were excluded because it was not considered ethical to ran-
domize patients with asthma and wheezing to placebo. A multistep
algorithm with high sensitivity in adults and children13,27 was used to
identify and exclude all individuals with asthma or possible asthma and
is included as a supplement. Briefly, any individual who carried a diag-
nosis of asthma or a history of using asthma medications was excluded.
For individuals with no asthma diagnosis, they were excluded if they
had any three of the following criteria: (1) Wheeze causing shortness
of breath, (2) wheeze without colds, (3) wheeze with exercise, and (4)
family history of asthma in a parent. All data were collected at the
Mount Sinai Medical Center (inpatient, ED, ambulatory clinics) or via
telephone.
2.3 | Study therapy and adaptive randomization
Participants were randomized in a 2:1 fashion to receive once-daily
inhaled mometasone furoate 220 mcg twisthaler or placebo for 16
weeks in addition to standard SCD care. The 2:1 allocation ratio was
chosen to (1) demonstrate the feasibility of unequal allocation schema
if necessary in future trials and (2) to generate safety data for mometa-
sone (by exposing more patients to active drug). Participants were
observed for an additional 4-week washout period after study comple-
tion (up to 20 weeks) however if patients felt marked symptom
improvement they were allowed to continue the study medication
(instead of washing out) at the discretion of their healthcare provider.
To ensure equal allocation of patients on hydroxyurea and equal alloca-
tion of patients with low, medium, and high rates of ED utilization, a
covariate-balancing, adaptive, biased-coin randomization algorithm was
employed.28 Briefly, the adaptive, biased-coin changed the probability
of treatment assignment based on the degree of existing imbalance
between groups (with respect to hydroxyurea use and prior rate of ED
utilization) for participants already in the trial. Unlike a stratified block
randomization, the biased coin algorithm altered probability (between
10% and 90%) but never made deterministic assignments to maintain
balance. This approach was chosen because it made masking of treat-
ment assignment more feasible but maintained a similar degree of
covariate balance to traditional stratified block randomization. Random-
ization assignments were performed by a separate, unblinded research
coordinator who was not responsible for data collection or assessment.
Participants, physicians, investigators, and data collectors were all
blinded to treatment assignment.
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2.4 | Measures to improve adherence and reduce
attrition
Adherence was assessed with dose counters on mometasone twist-
halers (placebo inhalers did not have dose counters and had a different
appearance than mometasone inhalers—detailed description of proce-
dures to maintain complete blinding of patients, providers, data collec-
tors, and analyzers are available in the supplement) and self-reported
adherence via follow-up phone calls for placebo. In addition, the medi-
cation adherence report scale for asthma (a 10 question tool scored
between 0 and 5 with higher scores indicating greater adherence)29,30
was administered to all patients to evaluate its utility in measuring
inhaler adherence in people with SCD. To improve adherence, a training
module was adapted from the National Asthma Education and
Prevention Program and the NIH Breathe Easier module.31 The module
included training and education on proper use of ICS, medication side
effects and mechanism of action (in lay-person terms), inhaler technique
and a 10-min structured coaching session to improve medication
adherence (see Supporting Information).
2.5 | Efficacy and safety assessments
Participants were assessed in-person at trial entry, at 8-weeks and at
16-weeks (study completion). At study entry and 8-weeks, assessments
included ASCQ-Me (NHLBI developed SCD quality of life measure-
ment tool) pain domain, spirometry with bronchodilator, eNO, periph-
eral blood testing (standard-of-care tests and peripheral-blood markers
of inflammatory activation) and side-effect questionnaires. Procedures
for pulmonary function testing were identical to those used for the
Sleep and Asthma Cohort22 and are included as a supplement. Adverse
events were assessed for every hospital visit, via questionnaire at each
in-person assessment, and at follow-up phone calls, which occurred at
2-weeks, 4-weeks and 12-weeks. Participants also filled out daily pain
diaries (derived from the Pain in Sickle Cell Epidemiology Study—PiS-
CES)32 for the 16-week duration of the study and the 4-week washout
period. Clinical events including hospital admissions, ED visits and ICU
stays were assessed via chart review and via in-person assessments at
2, 8, 10, 16, and 20 weeks. Trial safety was assessed via an independ-
ent data safety and monitoring board (DSMB). The DSMB met every
six months with an interim analysis performed after 20 participants to
assess trial safety (only adverse events were reviewed including deaths,
pneumonia and ICU visits without frequentist hypothesis testing).
There were no a priori safety or futility parameters for the study. There
were no serious adverse events at the interim analysis and the study
was allowed to continue to completion.
2.6 | Serum quantification of cytokines
Blood for serum was collected in Vacutainer serum separator tubes
(BD, Franklin Lakes, NJ, USA). Tubes were stored cold for less than 6 h
until centrifugation. Serum was separated and stored at 2808C until
analysis. All cytokines were analyzed by a bead-based ELISA method
(R&D Systems, Minneapolis, MN) using a Luminex 200 (Luminex Cor-
poration, Austin, TX, USA). All samples were run in duplicate, and both
visits of each subject were analyzed simultaneously on the same plate,
eliminating any variability between assays.
2.7 | Statistical analyses
All statistical analyses were performed using SAS version 9.3. All data
were checked for missingness and statistical outliers and confirmed by
rechecking paper case-report forms for data-entry errors. Missing data
were missing at random and missingness was not related to treatment
assignment. Data were reviewed for distributional characteristics to
ensure that statistical assumptions were met prior to hypothesis test-
ing. Data were checked for statistically significant differences in impor-
tant variables (age, gender, steady-state fetal hemoglobin, steady-state
hemoglobin, steady-state WBC, prior rate of ED utilization) across
treatment groups. Bivariate analyses were performed to determine if
covariates were significantly associated with outcome data. The a priori
plan was to statistically adjust only for variables found to be associated
with the outcome variable (at a level of P value below 0.2) or if signifi-
cant between-group differences were found. For the primary patient-
reported outcome of pain scores over time, a random-intercepts, mixed
effect model was used with patient as a random effect. Treatment
assignment was considered as a fixed effect. An unstructured variance-
covariance structure was chosen for the model because it yielded the
lowest Akaike information criterion. Because a significant difference in
age between groups was found, all results were adjusted for age. For
continuous outcomes, linear regression was used; for count data, nega-
tive binomial regression; and for binary data, logistic regression. To
determine the effect of mometasone on the odds of admission to the
hospital during any visit, a generalized estimating equation was used
(proc GENMOD with a repeated statement for subject ID, predictors
included treatment assignment and age, dependent variable was admis-
sion to the hospital) with robust estimation of variances and a binary
logit link. No adjustments were made for multiple comparisons of
secondary outcome data.
3 | RESULTS
3.1 | Patient and treatment characteristics
Between February 2014 and October 2016, a total of 54 patients
were consented and randomized into the study, with two patients
lost to follow-up prior to data collection leaving 52 patients available
for the intent-to-treat analysis and 45 patients eligible for the per-
protocol analysis (Figure 1). For the primary outcome of feasibility
(calculated as the number who complete the study divided by the
number consented), the result was 96% (52 of 54, 95% CI 87%-99%)
for the intent-to-treat analysis and 83% (45 of 54, 95% CI 71%-
91%) for the per-protocol analysis. Patient characteristics are pro-
vided in Table 1. At study entry, participants in the placebo group
were older than the mometasone group (mean 36 vs. 30 years,
P50.02). There were no other statistically significant differences in
baseline characteristics between treatment groups nor were there
statistically significant associations between covariates (age, gender,
baseline laboratory values) and outcome variables. Rates of obstruc-
tive lung disease were low in both groups and there were no cases
of response to bronchodilator during spirometry. ENO levels were
normal in both groups at baseline.
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3.2 | Inhaled corticosteroids reduce patient-reported
pain
For the outcome of pain score over time, the adjusted treatment effect
of mometasone was a reduction in daily pain score of 1.42 points
(95%CI 0.61-2.21, P50.001). Figure 2 shows pain scores by week
stratified by treatment group. The following secondary clinical out-
comes numerically favored mometasone over placebo but were not
statistically significant. Changes in ASCQ-Me pain impact were 5.2
points (on a 100-point scale) better (reductions indicate improved qual-
ity of life) for the mometasone group than placebo (95% CI 218.90 to
8.49, P50.46). For patients who had at least one ED visit, the absolute
difference in rate of admission (or 24-h observation) to the hospital
was 12% lower for the mometasone group (Risk Ratio50.79, 95% CI
0.45-1.38, P50.40). Patients in the mometasone group spent, on aver-
age after statistical adjustment, 1.88 fewer days in the hospital (95% CI
25.95 to 2.19, P50.36).
FIGURE 1 Patient Flow CONSORT Diagram. * 1 participant in each group was lost to follow up prior to data collection and excluded
from analyses. Others (n53) were still included in the intent to treat analysis because they completed follow up questionnaires, spirometry,
eNO, and blood draws prior to being lost
FIGURE 2 Weekly mean pain diary scores of Mometasone vs.
Placebo groups. Mometasone was associated with a mean pain
score reduction of 1.42 points over time (95%CI 0.61-2.21,
P>0.001). Error bars indicate 95% confidence intervals [Color
figure can be viewed at wileyonlinelibrary.com]
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3.3 | Secondary biomarker outcomes
For the a priori biomarker outcome of change in sVCAM (Table 2) as a
surrogate for vascular injury, the placebo group experienced a mean
increase of 170.25 ng/mL and the mometasone group experienced a
decrease of 182.47 ng/mL (adjusted treatment effect 526.94 ng/mL,
95% CI 1003.23-50.66, P50.03). This corresponded to a percent
change in sVCAM for the placebo vs. mometasone group of 8.82%
vs 24.86%. There were no significant between-group differences in
TNF-a, IFN-g, IL1b, IL-6, E-selectin, P-selectin, IL-4, IL-2, or IL-13
(see Supporting Information). Change in reticulocyte percentage sig-
nificantly favored the mometasone group (absolute difference
21.86%, 95% CI 23.66 to 20.06, P50.04) however change in
absolute reticulocyte count was not significant. Other clinical
TABLE 1 Participant characteristics
Characteristic Placebo (N5 17) Mometasone (N535) P
Male sex, N(%) 11 (64%) 17 (49%) 0.4
Age (y)
Mean (SD) 36 (9.81) 30 (8.56) 0.02
Hemoglobin diagnosis 1.0
HbSS 16 34
Hb Sb0 thalassemia 1 1
Medical History
HU therapy N (%) 11 (64.7%) 23 (65.7%) 1.0
History of eczema 1 (6%) 4 (11%) 1.0
History of allergies 6 (35%) 14 (40%) 0.3
Smoking 0.8
Never, N(%) 9 (52%) 22 (63%)
Smoked in past but not now, N(%) 6 (35%) 10 (29%)
Current smoker 2 (12%) 3 (9%)
Steady state Hemoglobin
Mean(SD) 9.01 (1.13) 8.71 (1.49) 0.5
Steady State Hemoglobin F %
Mean (SD) 10.56 (7.32) 9.03 (6.56) 0.5
Spirometry at study entry
FEV1% Predicted mean (SD) 86.67(21.88) 87.83 (12.90) 0.9
FVC % Predicted mean (SD) 87.47 (12.36) 92.00 (16.08) 0.3
FEV1/FVC mean (SD) 80.14 (14.95) 83.24 (3.56) 0.4
Positive bronchodilator responsea 0 0 0.6
Exhaled NO ppb mean (SD) 15.35 (10.11) 14.00 (6.27)
Prior ED Utilization (past 12 months) 0.4
0-5 visits—n (%) 12 (71%) 30 (86%)
6-10 visits—n (%) 4 (24%) 4 (11%)
11-15 visits—n (%) 1 (6%) 1 (3%)
Laboratory values at study entry
Hemoglobin g/dL
Mean (SD) 8.92 (1.59) 8.55 (1.54) 0.4
WBC count, x 103/mL
Mean (SD) 11.84 (4.48) 10.55 (3.81) 0.3
Hemoglobin F %
Mean (SD) 9.19 (7.27) 8.52 (6.09) 0.7
Reticulocyte count %
Mean (SD) 7.71 (2.86) 7.74 (4.03) 0.97
Lactate dehydrogenase IU/I
Mean (SD) 367.60 (207.08) 440.21 (182.47) 0.5
sVCAM mg/mL
Mean (SD) 2378.9 (987.4) 2712.7 (1478.8) 0.4
aPositive bronchodilator response defined as an improvement of greater than 12% in FEV1.
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TABLE 2 Outcomes
Adjusted intent to treat analyses
Placebo (17) Drug (35) Treat-ment Effect 95%CI P value
Patient-reported outcomes
Pain score over timea
Mean (SD) 2.82 (2.21) 2.09 (2.55) 21.42 20.61 to 22.21 0.001
LS mean (SE)b 3.09 (0.23) 1.67 (0.34)
D ASCQ-Me Pain domainc
Mean (SD) 6.9 (24.0) 2.8 (22.7) 25.2 219.7 to 9.29 0.47
LS mean (SE)b 6.9 (6.80) 2.8 (4.86)
Asthma control test (0-25)c
· Total score 17.1 (1.78) 17.7 (2.25) 0.20 21.13 to 1.53 0.3
· Respiratory symptoms interfering with work? 7 (41.2%) 9 (26.5%)
· Shortness of breath? 6 (35.3%) 5 (14.7%)
· Nighttime symptoms? 6 (35.3%) 7 (20.6%)
· Wheezing controlled? 12 (75%) 22 (66.7%)
Clinical outcomes
ED Visitsd
Mean (SD) 1.12 (1.87) 0.97 (1.52) 0.80e 0.35-1.84 0.60
Predicted count (SE)f 1.05 (0.44) 1.00 (0.31)
Observation admitsd
Mean (SD) 0.59 (1.18) 0.37 (0.77) 0.58e 0.21-1.62 0.30
Predicted count (SE)f 0.57 (0.52) 0.38 (0.41)
Admissionsd
Mean (SD) 0.47 (1.23) 0.37 (0.77) 0.73e 0.25-2.13 0.56
Predicted count (SE)f 0.45 (0.54) 0.38 (0.41)
Overnight stays (admit or obs)d
Mean (SD) 0.82 (1.67) 0.60 (1.09) 0.69e 0.28-1.71 0.43
Predicted count (SE)f 0.79 (0.45) 0.61 (0.34)
Admit rateg
Mean (SD) 0.42 (0.39) 0.38 (0.36) 0.85e 0.33-2.15 0.74
Predicted rate (SE) 0.42 (0.46) 0.36 (0.31)
Admit/obs rateg
Mean (SD) 0.74 (0.36) 0.62 (0.38) 0.79e 0.45-1.38 0.40
Predicted rate (SE) 0.73 (0.25) 0.58 (0.21)
Inpatient daysd
Mean (SD) 4.09 (9.25) 2.67 (5.11) 21.88 25.95 to 2.19 0.36
LS Mean (SE)b 3.95 (1.91) 2.68 (1.38)
Biological outcomes
D Hemoglobin g/dLc
Mean (SD) 20.01 (1.31) 0.30 (0.96) 0.50 20.21 to 1.20 0.16
LS mean (SE)b 0.00 (0.32) 0.29 (0.23)
D Reticulocytes %c
Mean (SD) 0.39 (2.85) 21.16 (2.63) 21.86 23.66 to 20.06 0.04
LS mean (SE)b 0.37 (0.82) 21.12 (0.62)
D Reticulocytes 3 103/mLc
Mean (SD) 0.07 (0.52) 20.15 (0.39) 20.21 20.52 to 0.10 0.18
LS mean (SE)b 0.07 (0.14) 20.15 (0.10)
(Continues)
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markers of hemolysis were not statistically significant including
change in hemoglobin levels (absolute difference50.5 g/dL, 95% CI
20.21 to 1.20, P50.16) and change in LDH levels (–111.99, 95% CI
2272.49 to 48.51, P50.16). The primary marker of pulmonary
inflammation, change in eNO, was not significantly different
between groups. There were no significant differences between
groups with respect to changes in spirometry over time.
3.4 | Safety, adherence, and attrition
There were no deaths, cases of pneumonia or acute chest syndrome
during the study period. Rates of nonserious adverse events including
hoarseness of voice, thrush and sore throat were numerically higher
for the mometasone group but were not statistically significant (Table
3). The rate of overall medication adherence was 92.6% for the placebo
group and 84.7% in the mometasone group (mean difference 7.9%,
95% CI 21.35 to 17.14, P50.09). Individuals in the mometasone
group had a significantly lower average score on the medication adher-
ence report scale (4.51 vs. 4.18, mean difference50.33, 95% CI 0.06-
0.60, P50.02). Post hoc analyses stratified by patient-reported side
effects (including hoarseness, thrush, and sore throat) did not show a
relationship between lower medication adherence and presence of side
effects. The medication adherence report scale had a statistically signif-
icant but moderate correlation with actual medication adherence
(r50.40, P50.01). With true medication adherence defined as having
taken more than 70% of prescribed doses, the medication adherence
report scale had an area under the receiver operating characteristic
curve of 0.74 (95% CI 0.56-0.92) and the cutoff with maximal
TABLE 2 (Continued)
Adjusted intent to treat analyses
Placebo (17) Drug (35) Treat-ment Effect 95%CI P value
D WBC 3 103/mLc
Mean (SD) 20.61 (3.70) 20.55 (2.80) 0.15 21.94 to 2.23 0.89
LS mean (SE)b 20.54 (0.94) 20.57 (0.67)
D Plateletsc
Mean (SD) 4.33 (127.75) 241.36 (88.14) 227.44 293.79 to 38.92 0.41
LS mean (SE)b 2.50 (29.98) 241.09 (21.28)
D Neutrophils 3 103/mLc
Mean (SD) 20.82 (3.08) 20.31 (2.92) 0.51 21.54 to 2.56 0.50
LS mean (SE)b 20.77 (0.93) 20.33 (0.64)
D LDHc
Mean (SD) 47.5 (117.15) 264.81 (132.37) 2111.99 2272.49 to 48.51 0.16
LS mean (SE)b 47.39 (76.06) 265.19 (43.30)
D sVCAM ng/mLc
Mean (SD) 170.25 (814.74) 2182.47 (785.21) 2526.94 21003.23 to 250.66 0.03
LS mean (SE)b 169.88 (215.59) 2182.39 (158.85)
Percent change (SD) 8.82% (34.60) 24.86% (29.17) 13.67
D eNO (ppb)c
Mean (SD) 2.71 (6.92) 0.63 (9.63) 22.47 28.06 to 3.12 0.38
LS mean (SE)b 2.73 (2.52) 0.58 (1.84)
D FEV1%predictedc
Mean (SD) 22.94 (5.15) 0.58 (7.69) 2.67 21.70 to 70.4 0.23
LS mean (SE)b 22.99 (1.96) 0.66 (1.50)
D FVC % predictedc
Mean (SD) 21.29 (4.37) 0.48 (6.53) 1.39 22.37 to 5.15 0.46
LS mean (SE)b 21.32 (1.69) 0.60 (1.29)
D FEV1/FVCc
Mean (SD) 21.41 (3.39) 20.71 (3.42) 0.39 21.78 to 2.56 0.72
LS mean (SE)b 21.44 (0.97) 20.73 (0.74)
All values adjusted for participant age.
aRandom-intercepts, mixed effect model with patient as a random effect.




fPredicted counts obtained via negative binomial regression.
gGeneralized estimating equation with “REPEATED” statement for subject ID and binary logit link.
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discrimination was a score of 4.5 out of 5 which had 47% sensitivity
and 100% specificity for identification of medication adherence.
With respect to trial attrition, there were 2 patients lost to follow-
up prior to collection of any outcome data at 1 (placebo) and 4 (mome-
tasone) weeks (one dropped out of the trial after one week, the other
moved away) who did not contribute data and were not included in
the analyses. Of the remaining 52 participants, 3 were lost to follow-up
between 8 and 10-weeks but were included in all the biological and
clinical intent-to-treat analyses (Figure 1). A complete description of all
5 cases of attrition is provided in the supplement.
4 | DISCUSSION
Here we report results of a single center, randomized, placebo-controlled,
triple-blinded feasibility study of ICS for nonasthmatic individuals with
SCD. While the primary goals of the study were to demonstrate protocol
fidelity and feasibility, there was also a statistically significant benefit with
respect to the a priori clinical outcome: daily pain diary score. Prior studies
have found a minimum clinically significant difference between two pain
scores to be 1.3 points on a 0-10 scale for acute pain33 and participants
in the current study experienced a mean daily improvement in pain score
of 1.42 points over four months. With multiple measurements (as were
done in this study), the minimum clinically important difference has been
shown to decrease further.34 The findings reported herein provide an ini-
tial indication that ICS may be a useful adjuvant therapy for nonasthmatic
individuals with SCD.
In addition to the main clinical outcome of pain diary scores, the
trial also showed a statistically significant benefit for ICS with respect
to change in sVCAM. This cytokine was chosen as the primary marker
of vascular injury for because higher sVCAM levels are correlated with
increased SCD morbidity and mortality.35–39 It was also chosen
because sVCAM was measured in peripheral blood away from the site
of action of the drug (the lung) and the dose of inhaled mometasone
used in this trial does not achieve detectable levels in the blood. Retic-
ulocyte percent, a clinical marker of hemolytic burden, also showed a
statistically significant benefit for ICS and a similar, nonsignificant result
was seen with serum LDH and absolute reticulocyte count. These bio-
logical assays worsened for the placebo group during the trial. This was
not unexpected as we enrolled only individuals who had recent epi-
sodes of cough and wheeze; a group we have previously demonstrated
to have high rates of vaso-occlusive complications.13 Other biomarkers
including IFN-g and several interleukins did not show substantial
changes with mometasone. We speculate that this is because mometa-
sone works by improving red cell oxygenation in the lung thereby
reducing red cell sickling, membrane damage and hemolysis. Many of
the cytokines which did not show a difference between groups were
markers of the innate and adaptive immune response which might not
be as directly affected by red cell damage as are sVCAM and the other
markers of hemolysis (LDH and reticulocyte count) which did show a
difference. With respect to ED visits, admissions and inpatient days,
the results numerically favored ICS but were not statistically significant.
There were no clinically meaningful changes in either group with eNO.
This is consistent with the findings of Cohen et al. in the Sleep and
Asthma Cohort22 and suggests that eNO levels in patients with SCD
may not be a marker of steroid responsive eosinophilic inflammation.
The lack of difference between groups with spirometry was likely
because individuals with asthma were screened out and most had nor-
mal spirometry at entry. Another important strength of the study is
that there was no observed increase in the rate of pulmonary infec-
tions or serious adverse events which provides important preliminary
safety data for ICS in SCD.
To our knowledge, there are no other published clinical trials of
asthma controller medications for treatment of SCD. With respect to
protocol fidelity, we demonstrated high rates of adherence to study
medication with low rates of loss to follow-up. The once-daily dosing
of inhaled mometasone furoate may have contributed to the high rates
of adherence observed in this trial. We also demonstrated the feasibil-
ity of an adaptive, covariate-balancing, biased coin randomization to
minimize potential bias without making deterministic treatment assign-
ments. Maintaining adherence to asthma control medicine is a tremen-
dous clinical challenge, and our trial evaluated, in individuals with SCD,
techniques validated in the general population for improving adherence
and measuring adherence to ICS. In our cohort, the medication adher-
ence report scale had similar correlation to actual medication adher-
ence (r50.40 in the current trial vs. 0.42 previously) similar area under
the ROC curve (0.74 in the current trial vs. 0.75 previously) but we
found higher specificity (100% vs 69.4% previously) and lower sensitiv-
ity (47% vs. 82.4% previously).29,30 As with previous studies of the
medication adherence report scale, a cutoff of 4.5 had the greatest
discriminatory value. The National Asthma Education and Prevention
Program has a number of carefully constructed tools to improve adher-
ence to asthma controller medication and this trial used an adapted
version of these materials. These adapted tools were easy to adminis-
ter and may be useful for future studies of ICS in SCD and for clinical
use of ICS in SCD.
TABLE 3 Adverse events
Intent to treat analysis
Placebo (17) Drug (35) Odds ratio 95%CI P value
Hoarseness of voice n(%) 4 (23.5%) 15 (42.9%) 1.34 0.48-3.74 0.57
Thrush n(%) 0 2 (5.7%) 1.16 0.08-17.42 0.91
Sore throat n(%) 5 (29.4%) 15 (42.9%) 1.14 0.42-3.12 0.80
Pneumonia 0 0 NA
Acute chest syndrome 0 0 NA
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The most important limitations of the study are the small sample
size and the fact that it was conducted at a single center. Single center
trials historically provide larger estimates of treatment effect than mul-
ticenter trials40 so the results reported here must be interpreted with
caution. Additionally, rates of adherence to medication were lower in
the mometasone group. This would be expected to bias the intent to
treat analyses towards the null hypothesis. Stratified analyses did not
suggest that measured side effects played a role in the lower adher-
ence, however anecdotally some participants reported an unpleasant
taste of the mometasone (something we did not measure in the trial)
which may have contributed to lower adherence. Increased pulmonary
capillary blood volume has emerged as an important potential etiology
of the alterations in lung function in SCD.25,26 Unfortunately this trial
was designed prior to the publication of this literature, however the
effects of ICS on pulmonary capillary blood flow should be assessed in
future studies. Further investigation into the potential mechanisms of
benefit for ICS in SCD is also warranted.
In conclusion, this single center, triple blind, placebo controlled trial
provides preliminary evidence of clinical and biological benefit of ICS in
patients with SCD who do not have asthma but report recent cough or
wheeze. Future studies to improve generalizability of these findings
should be conducted at multiple centers and should evaluate longer
durations of treatment.
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